share_log

Weihai Baihe Biology Technological's (SHSE:603102) Problems Go Beyond Weak Profit

Weihai Baihe Biology Technological's (SHSE:603102) Problems Go Beyond Weak Profit

威海百合生物技術(SHSE:603102)的問題不僅僅是利潤下滑
Simply Wall St ·  11/01 08:17

The subdued market reaction suggests that Weihai Baihe Biology Technological Co., Ltd.'s (SHSE:603102) recent earnings didn't contain any surprises. We think that investors are worried about some weaknesses underlying the earnings.

市場反應平淡表明威海百合生物技術有限公司(SHSE:603102)最近的收益沒有任何意外。我們認爲投資者擔心一些潛在的盈利弱點。

big
SHSE:603102 Earnings and Revenue History November 1st 2024
SHSE:603102盈利和營業收入歷史 2024年11月1日

The Impact Of Unusual Items On Profit

除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。

For anyone who wants to understand Weihai Baihe Biology Technological's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥13m worth of unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. If Weihai Baihe Biology Technological doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

對於想要了解威海百合生物技術超過法定數字的利潤的人,重要的是要注意,在過去12個月裏,法定利潤中的1300萬人民幣來自於飛凡項目。我們不得不承認,更高的利潤通常讓我們感到樂觀,但我們更希望利潤能夠持續。當我們分析全球大多數上市公司時,我們發現重大的飛凡項目通常不會重複。畢竟,這正是會計術語所暗示的。如果威海百合生物技術未能看到該貢獻重複,那麼其他條件不變,我們預計其今年的利潤會下降。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Weihai Baihe Biology Technological.

注意:我們始終建議投資者檢查資產負債表的實力。點擊這裏查看我們對威海百合生物技術資產負債表分析。

Our Take On Weihai Baihe Biology Technological's Profit Performance

我們對威海百合生物技術的利潤表現的看法

We'd posit that Weihai Baihe Biology Technological's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Therefore, it seems possible to us that Weihai Baihe Biology Technological's true underlying earnings power is actually less than its statutory profit. In further bad news, its earnings per share decreased in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. You'd be interested to know, that we found 1 warning sign for Weihai Baihe Biology Technological and you'll want to know about it.

我們認爲威海百和生物科技的法定收入並不是對持續生產力的清晰指標,因爲存在大額飛凡項目。因此,我們認爲威海百和生物科技的真正基本收入實際上可能低於其法定利潤。更糟糕的是,其每股收益在過去一年內下降。最終,如果您想正確了解這家公司,除了上述因素外,還需要考慮更多因素。請記住,分析股票時需要注意相關風險。您可能會感興趣的是,我們發現了威海百和生物科技的1個風險警示信號,您會想知道的。

Today we've zoomed in on a single data point to better understand the nature of Weihai Baihe Biology Technological's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

今天我們關注了單一的數據點,以更好地了解威海百和生物科技利潤的性質。但還有許多其他方法可以了解公司。一些人認爲股權回報率高是公司質量良好的一個徵兆。因此,您可能希望查看提供高股權回報率的公司的免費收藏,或者股權所有權高的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論